Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer
Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carci...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
John Wiley and Sons Inc.
2014
|
| _version_ | 1797072019720765440 |
|---|---|
| author | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjær, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D |
| author_facet | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjær, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D |
| author_sort | Aleksandrova, K |
| collection | OXFORD |
| description | Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations=1.22; 95% CI=1.02-1.46; P = 0.03; 1.90; 95% CI=1.30-2.77; P = 0.001; 2.25; 95% CI=1.43-3.54; P = 0.0005; and 2.09; 95% CI=1.19-3.67; P = 0.01, respectively). CRP was associated also with risk of GBTC (IRR=1.22; 95% CI=1.05-1.42; P = 0.01). GLDH was associated with risks of HCC (IRR=1.62; 95% CI=1.25-2.11; P = 0.0003) and IBD (IRR=10.5; 95% CI=2.20-50.90; P = 0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. Conclusion: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. © 2014 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. |
| first_indexed | 2024-03-06T23:01:37Z |
| format | Journal article |
| id | oxford-uuid:6252820d-86c5-450d-90b2-d3b975d591aa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:01:37Z |
| publishDate | 2014 |
| publisher | John Wiley and Sons Inc. |
| record_format | dspace |
| spelling | oxford-uuid:6252820d-86c5-450d-90b2-d3b975d591aa2022-03-26T18:05:39ZInflammatory and metabolic biomarkers and risk of liver and biliary tract cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6252820d-86c5-450d-90b2-d3b975d591aaEnglishSymplectic Elements at OxfordJohn Wiley and Sons Inc.2014Aleksandrova, KBoeing, HNöthlings, UJenab, MFedirko, VKaaks, RLukanova, ATrichopoulou, ATrichopoulos, DBoffetta, PTrepo, EWesthpal, SDuarte-Salles, TStepien, MOvervad, KTjønneland, AHalkjær, JBoutron-Ruault, MDossus, LRacine, ALagiou, PBamia, CBenetou, VAgnoli, CPalli, DObesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations=1.22; 95% CI=1.02-1.46; P = 0.03; 1.90; 95% CI=1.30-2.77; P = 0.001; 2.25; 95% CI=1.43-3.54; P = 0.0005; and 2.09; 95% CI=1.19-3.67; P = 0.01, respectively). CRP was associated also with risk of GBTC (IRR=1.22; 95% CI=1.05-1.42; P = 0.01). GLDH was associated with risks of HCC (IRR=1.62; 95% CI=1.25-2.11; P = 0.0003) and IBD (IRR=10.5; 95% CI=2.20-50.90; P = 0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. Conclusion: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. © 2014 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. |
| spellingShingle | Aleksandrova, K Boeing, H Nöthlings, U Jenab, M Fedirko, V Kaaks, R Lukanova, A Trichopoulou, A Trichopoulos, D Boffetta, P Trepo, E Westhpal, S Duarte-Salles, T Stepien, M Overvad, K Tjønneland, A Halkjær, J Boutron-Ruault, M Dossus, L Racine, A Lagiou, P Bamia, C Benetou, V Agnoli, C Palli, D Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title_full | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title_fullStr | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title_full_unstemmed | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title_short | Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| title_sort | inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer |
| work_keys_str_mv | AT aleksandrovak inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boeingh inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT nothlingsu inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT jenabm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT fedirkov inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT kaaksr inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT lukanovaa inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trichopouloua inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trichopoulosd inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boffettap inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT trepoe inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT westhpals inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT duartesallest inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT stepienm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT overvadk inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT tjønnelanda inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT halkjærj inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT boutronruaultm inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT dossusl inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT racinea inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT lagioup inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT bamiac inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT benetouv inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT agnolic inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer AT pallid inflammatoryandmetabolicbiomarkersandriskofliverandbiliarytractcancer |